Sarah Cannon
December 02, 2015

NASHVILLE, Tenn., Dec. 2, 2015 Sarah Cannon announced today that the American Society of Hematology (ASH) has selected 35 abstracts authored by members of the Sarah Cannon Blood Cancer Network to be presented at the 2015 ASH Meeting and Exposition. Hosted in Orlando from Dec. 5 - 8, the meeting is the world’s leading malignant and non-malignant hematology research event and brings together more than 20,000 hematology professionals to discuss the latest breakthroughs in blood cancer research and treatment.

“The biggest news being reviewed at this year’s meeting is the study of immunotherapies, including the emergence of new trials utilizing CAR T-Cell therapy,” said Howard (“Skip”) Burris, MD, President of Clinical Operations and Chief Medical Officer for Sarah Cannon. “We look forward to discussing the latest developments with our colleagues, as well as sharing our insights on novel targeted treatments that are showing progress in advancing blood cancer care standards.”

The 35 abstracts represent studies being conducted by principal investigators from Sarah Cannon research sites affiliated with Tennessee Oncology, Florida Cancer Specialists & Research Institute and Oncology Hematology Care, Inc., as well as other Sarah Cannon Blood Cancer Network physicians from Colorado Blood Cancer Institute, Texas Transplant Institute and OU Medical Center.  

“The Sarah Cannon Blood Cancer Network brings together some of the world’s top blood cancer specialists and researchers under one network with the common goal to advance care for blood cancer patients,” said Fred LeMaistre, physician in chief of blood cancers, Sarah Cannon. “Through our approach, we are ensuring that patients have convenient access to cutting-edge treatment options and higher care standards that contribute to improved outcomes.”

About The Sarah Cannon Blood Cancer Network

The Sarah Cannon Blood Cancer Network is one of the largest providers of blood cancer care including blood and marrow transplantation (BMT) across the United States and United Kingdom. Its network conducts approximately 1,000 transplants annually through seven FACT accredited transplant centers and has treated approximately 12,000 patients since the inception of its first program. Through its commitment to the highest level of quality standards, infrastructure, technology, training and research, the Sarah Cannon Blood Cancer Network provides an unparalleled experience for patients seeking treatment. For more information about the Blood Cancer Network and Sarah Cannon’s full suite of oncology services, visit